Author/Authors :
Anson, David University of Illinois College of Medicine Peoria - Peoria - IL, USA , Norton, Joseph Department of Internal Medicine - University of Illinois College of Medicine Peoria - Peoria - IL, USA , Chaucer, Benjamin Department of Internal Medicine - University of Illinois College of Medicine Peoria - Peoria - IL, USA , Bansal, Saurabh Department of Internal Medicine - University of Illinois College of Medicine Peoria - Peoria - IL, USA
Abstract :
Immune-mediated colitis is an uncommon but well-documented adverse event in patients receiving nivolumab or ipilimumabtherapy. In this report, we present a 69-year-old man who developed severe hypokalemia and colitis with significant correctedQ-T segment (QTc) prolongation as a result of combination nivolumab-ipilimumab immunotherapy for clear cell renal cellcarcinoma.
Keywords :
Ipilimumab - , Nivolumab - , Induced Colitis Causing Severe Hypokalemia , QTc Prolongation , Immune-mediated colitis
